» Articles » PMID: 25202979

Mesothelial Cells Promote Early Ovarian Cancer Metastasis Through Fibronectin Secretion

Abstract

Ovarian cancer (OvCa) metastasizes to organs in the abdominal cavity, such as the omentum, which are covered by a single layer of mesothelial cells. Mesothelial cells are generally thought to be "bystanders" to the metastatic process and simply displaced by OvCa cells to access the submesothelial extracellular matrix. Here, using organotypic 3D cultures, we found that primary human mesothelial cells secrete fibronectin in the presence of OvCa cells. Moreover, we evaluated the tumor stroma of 108 human omental metastases and determined that fibronectin was consistently overexpressed in these patients. Blocking fibronectin production in primary mesothelial cells in vitro or in murine models, either genetically (fibronectin 1 floxed mouse model) or via siRNA, decreased adhesion, invasion, proliferation, and metastasis of OvCa cells. Using a coculture model, we determined that OvCa cells secrete TGF-β1, which in turn activates a TGF-β receptor/RAC1/SMAD-dependent signaling pathway in the mesothelial cells that promotes a mesenchymal phenotype and transcriptional upregulation of fibronectin. Additionally, blocking α5 or β1 integrin function with antibodies reduced metastasis in an orthotopic preclinical model of OvCa metastasis. These findings indicate that cancer-associated mesothelial cells promote colonization during the initial steps of OvCa metastasis and suggest that mesothelial cells actively contribute to metastasis.

Citing Articles

The extracellular matrix protein type I collagen and fibronectin are regulated by β-arrestin-1/endothelin axis in human ovarian fibroblasts.

Masi I, Ottavi F, Caprara V, Rio D, Kunkl M, Spadaro F J Exp Clin Cancer Res. 2025; 44(1):64.

PMID: 39985042 PMC: 11844176. DOI: 10.1186/s13046-025-03327-5.


Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies.

Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.

PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.


Macrophage diversity in cancer dissemination and metastasis.

Mantovani A, Marchesi F, Di Mitri D, Garlanda C Cell Mol Immunol. 2024; 21(11):1201-1214.

PMID: 39402303 PMC: 11528009. DOI: 10.1038/s41423-024-01216-z.


Exploiting Matrix Stiffness to Overcome Drug Resistance.

Aydin H, Ozcelikkale A, Acar A ACS Biomater Sci Eng. 2024; 10(8):4682-4700.

PMID: 38967485 PMC: 11322920. DOI: 10.1021/acsbiomaterials.4c00445.


Gene Profiling of Circular RNAs in Keloid-prone Individuals and ceRNA Network Construction During Wound Healing.

Yang J, Zhu Z, Xu Y, Xu S, Zhang Y, Liu Z Aesthetic Plast Surg. 2024; 48(21):4534-4545.

PMID: 38914881 DOI: 10.1007/s00266-024-04139-2.


References
1.
Brunner M, Millon-Fremillon A, Chevalier G, Nakchbandi I, Mosher D, Block M . Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition. J Cell Biol. 2011; 194(2):307-22. PMC: 3144405. DOI: 10.1083/jcb.201007108. View

2.
Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

3.
Kenny H, Leonhardt P, Ladanyi A, Yamada S, Montag A, Im H . Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2010; 17(3):459-71. PMC: 3073583. DOI: 10.1158/1078-0432.CCR-10-2258. View

4.
Hapke S, Gawaz M, Dehne K, Kohler J, Marshall J, Graeff H . beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001; 21(6):2118-32. PMC: 86830. DOI: 10.1128/MCB.21.6.2118-2132.2001. View

5.
Mosher D . Binding of plasma fibronectin to cell layers of human skin fibroblasts. J Cell Biol. 1983; 97(2):466-72. PMC: 2112508. DOI: 10.1083/jcb.97.2.466. View